In the second study, researchers used automated imprint cytology (IC) in conjunction with the PlasmaBlade and assessed the relative thermal injury to breast tissue specimens and the ability to retrieve undamaged cells for IC analysis. They concluded that epithelial cells could be harvested by IC from the PlasmaBlade sample margins with less thermal injury and enhanced overall margin quality compared to traditional electrosurgery.

Additionally, a presentation by Dr. Attai on surgery and margin assessment using PEAK Surgical's pulsed plasma technology was included in a pre-meeting CME-accredited course on advancements in technology used to diagnose and treat diseases of the breast.

"The results of these PRECISE studies demonstrate the clinical benefits of the PEAK PlasmaBlade in helping to improve breast cancer diagnosis and treatment," said John Tighe, president and CEO of PEAK Surgical. "The PlasmaBlade clearly has an important role in the continuum of surgical care needed to treat breast cancer, including lumpectomy, mastectomy and breast reconstruction, due to its ability to dissect delicate tissue and improve clinical outcomes."

SOURCE PEAK Surgical, Inc.